Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R3R01 in Alport syndrome and primary steroid-resistant FSGS
NL-OMON58970Phase 2Completed
- Sponsor
- River 3 Renal Corp
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of R3R01 in Alport syndrome and focal segmental glomerulosclerosis (FSGS) (2 cohorts), sponsored by River 3 Renal Corp. Primary endpoints: Safety and tolerability, Change from baseline in proteinuria for Alport syndrome cohort and 1 more. Started Jan 2023; status: completed.
02
Drugs
R3R01
03
Conditions
Alport syndromefocal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NL-OMON58970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58970.